















**A** T cells and NK cells (n = 25,905)**B****C****D****E****F****G****H****I****J****K**

**Supplementary Figure S5. Characterizing ovarian cancer ascites immune cell subtypes, related to Figure 3.**

**A - H**, Main immune cell clusters identified in Fig. 1E were subclustered to annotate immune cell subtypes. UMAP plots colored by the identified subclusters and bar plots displaying each subcluster proportion are shown for T and NK cells (**A**), dendritic cells (**E**) and B cells (**G**). The average expression levels of subcluster marker genes are displayed as a dot plot separately for NK cells (**B**), CD4<sup>+</sup> T cells (**C**), CD8<sup>+</sup> T cells (**D**), dendritic cells (**F**) and B cells (**H**). **I** and **J**, Clever-1 (**I**) and available bexmarilimab epitope (**J**) abundancy on the surface of untreated CD11b<sup>+</sup>CD64<sup>+</sup> ovarian ascites cells were measured by flow cytometry and are shown separately for the R and NoR group. Mean  $\pm$  SD, unpaired t-test, each dot represents a single patient. **K**, Fluorescence intensity histograms of representative patients shown in (**J**). BEX, bexmarilimab; IgG4, isotype control for bexmarilimab; NoR, bexmarilimab non-responsive; R, bexmarilimab responsive.